Kedrion
Kedrion Biopharma, commonly referred to as Kedrion, is a leading global player in the biopharmaceutical industry, headquartered in Italy. Founded in 2001, the company has established a strong presence in major operational regions, including Europe and North America, focusing on the development and production of human plasma-derived therapies. Kedrion's core offerings include immunoglobulins, clotting factors, and albumin, which are essential for treating various medical conditions. What sets Kedrion apart is its commitment to quality and innovation, ensuring that its products meet the highest safety standards. With a robust market position, Kedrion has achieved significant milestones, including expanding its product portfolio and enhancing its global distribution network, solidifying its reputation as a trusted provider in the biopharmaceutical sector.
DitchCarbon Score
How does Kedrion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kedrion's score of 44 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kedrion's reported carbon emissions
In 2024, Kedrion reported total carbon emissions of approximately 16934800 kg CO2e for Scope 1, 25092000 kg CO2e for Scope 2 (market-based), and 92215000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes. Comparatively, in 2023, Kedrion's emissions were about 15210000 kg CO2e for Scope 1, 21905000 kg CO2e for Scope 2 (market-based), and 102043000 kg CO2e for Scope 3. Notably, there was a reduction in Scope 1 emissions from 2023 to 2024, indicating a positive trend in their operational efficiency. Kedrion's emissions data is cascaded from its parent company, Kedrion S.p.A., which is the source of their performance metrics. However, there are currently no specific reduction targets or climate pledges documented, suggesting that while emissions are being tracked, formal commitments to reduction initiatives may not yet be established. Overall, Kedrion's emissions profile highlights the importance of ongoing monitoring and potential future commitments to enhance their sustainability efforts in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 2,421 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kedrion is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
